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Incidence and risk factors for 
preeclampsia in a cohort of healthy 
nulliparous pregnant women: a 
nested case-control study
Jussara Mayrink1, Renato t. souza1, Francisco e. Feitosa2, edilberto A. Rocha Filho3, 
Débora F. Leite1,3, Janete Vettorazzi  4, Iracema M. Calderon5, Maria H. sousa6, 
Maria L. Costa1, philip N. Baker7, Jose G. Cecatti  1 & preterm sAMBA study group*
the objective of this study is to determine the incidence, socio-demographic and clinical risk factors for 
preeclampsia and associated maternal and perinatal adverse outcomes. this is a nested case-control 
derived from the multicentre cohort study Preterm SAMBA, in five different centres in Brazil, with 
nulliparous healthy pregnant women. Clinical data were prospectively collected, and risk factors were 
assessed comparatively between PE cases and controls using risk ratio (RR) (95% CI) plus multivariate 
analysis. Complete data were available for 1,165 participants. The incidence of preeclampsia was 7.5%. 
Body mass index determined at the first medical visit and diastolic blood pressure over 75 mmHg at 20 
weeks of gestation were independently associated with the occurrence of preeclampsia. Women with 
preeclampsia sustained a higher incidence of adverse maternal outcomes, including C-section (3.5 fold), 
preterm birth below 34 weeks of gestation (3.9 fold) and hospital stay longer than 5 days (5.8 fold)  
than controls. They also had worse perinatal outcomes, including lower birthweight (a mean 379 g 
lower), small for gestational age babies (RR 2.45 [1.52–3.95]), 5-minute Apgar score less than 7 (RR 2.11 
[1.03–4.29]), NICU admission (RR 3.34 [1.61–6.9]) and Neonatal Near Miss (3.65 [1.78–7.49]). Weight 
gain rate per week, obesity and diastolic blood pressure equal to or higher than 75 mmHg at 20 weeks of 
gestation were shown to be associated with preeclampsia. preeclampsia also led to a higher number of 
C-sections and prolonged hospital admission, in addition to worse neonatal outcomes.
Preeclampsia is considered an important cause of maternal mortality and severe maternal morbidity1. For every 
woman who dies, it is estimated that around 20 other women suffer from severe morbidity and disability2,3. In 
view of the social and economic implications of this condition, great effort has been made to expeditiously pre-
vent, diagnose and treat preeclampsia4–7.
The magnitude of the problem in some places across the world is still not fully known, especially in low and 
middle-income countries. In particular, the actual incidence of preeclampsia remains largely unknown8. There is 
usually suboptimal reporting of the disease, leading to constraints on public health applicability9. Another impor-
tant aspect is the identification of pregnant women at risk of developing preeclampsia, especially in nulliparous 
women with no track record of any pregnancy outcomes3. From clinical risk factors to ‘omics’ technology, there is 
still currently no single good predictor of preeclampsia10–15.
Clinical factors remain an inexpensive and rapid way to predict the occurrence of preeclampsia. This cur-
rent study intends to evaluate the incidence of preeclampsia and its sub-phenotypes (early-onset and late-onset), 
1Department of Obstetrics and Gynaecology, University of campinas (UnicAMP) School of Medical Sciences, 
campinas, SP, Brazil. 2MeAc – Maternity School of the federal University of ceará, fortaleza, ce, Brazil. 3Department 
of Maternal and child Health, Maternity Hospital, federal University of Pernambuco, Recife, Pe, Brazil. 4Department 
of Obstetrics and Gynaecology, Maternity Hospital, federal University of RS, Porto Alegre, RS, Brazil. 5Department 
of Obstetrics and Gynaecology, Botucatu School of Medicine, Unesp, Botucatu, SP, Brazil. 6Statistics Unit, Jundiai 
School of Medicine, Jundiaí, SP, Brazil. 7college of Life Sciences, Maurice Shock Building, University of Leicester, 
Leicester, UK. *A comprehensive list of consortium members appears at the end of the paper. correspondence and 
requests for materials should be addressed to J.G.c. (email: cecatti@unicamp.br)
Received: 24 January 2019
Accepted: 18 June 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:9517  | https://doi.org/10.1038/s41598-019-46011-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
socio-demographic and clinical risk factors for preeclampsia, as well as assess the ability to predict this disorder 
in a cohort of healthy nulliparous Brazilian pregnant women.
Results
Among 1,373 participants screened for eligibility in the Preterm SAMBA study, complete pregnancy outcome 
data were available for 1,165 women (Fig. 1). Preeclampsia developed in 87 (7.5%) participants of whom 14 
(16.1%) had early-onset preeclampsia while the remaining 73 were late-onset. The socio-demographic character-
istics of women who developed preeclampsia and controls are shown in Table 1. Among patient characteristics, 
the rate of weight gain per week equal to or more than 0.75 kg, obesity (BMI > 30.9 Kg/m2) and diastolic blood 
pressure equal to or higher than 75 mmHg at 20 weeks of gestation were associated with more than twice the risk 
of preeclampsia (Table 1).
Maternal and neonatal outcomes in preeclampsia were worse for both the mothers and their neonates 
(Table 2). Women with preeclampsia presented a relative risk of 3.58 for caesarean section, while hospital admis-
sion for 5 days or more was almost 6-fold higher. Women with preeclampsia had more preterm births at less 
than 34 weeks of gestation (3.97 fold) than controls. Neonates of women with preeclampsia had a significantly 
lower birthweight (a mean of 379 g lower), and there was a twofold to threefold higher occurrence of small for 
gestational age (SGA) babies, 5-minute Apgar scores less than 7, NICU admission and Neonatal Near Miss events. 
There was only one case of fetal death, occurring in a 26-year old woman, at 26 weeks of gestation. She was admit-
ted to hospital, complaining of a headache. Arterial blood pressure was 170 × 110 mmHg, protein in dipstick uri-
nalysis was +3 and no fetal heart beat was identified. The induction of labour lasted 24 hours, resulting in vaginal 
delivery of a baby weighing 620 g.
On multivariate analysis, diastolic blood pressure at 20 weeks of gestation and BMI at enrolment were inde-
pendently associated with the occurrence of preeclampsia, with an adjusted risk ratio of 1.04 (Table 3).
Discussion
Our study revealed that the incidence of preeclampsia was 7.5% in a nulliparous group of healthy pregnant 
women from three different Brazilian regions, which is higher than values obtained from other cohorts of nul-
liparous pregnant women16–18. Current analysis was able to identify only three factors significantly associated 
with the development of preeclampsia: weight gain rate per week, obesity and value of diastolic blood pressure 
measured at 20 weeks of gestation equal to or higher than 75 mmHg. The low number of preeclampsia cases in 
this sample probably prevented us from identifying additional factors, limiting the capacity to predict preeclamp-
sia by using a composition of factors. Not surprisingly, our findings on maternal and perinatal outcomes added 
Figure 1. Flowchart of women participating in the study.
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support to other studies, showing an increased frequency of Caesarean sections, preterm births, neonatal near 
misses, 5-minute Apgar scores less than 7 and low birth weight in pregnancies complicated by preeclampsia19,20. 
This higher proportion of adverse perinatal outcomes, including the lower birthweight, are also related to the 
increased occurrence of preterm births among preeclamptic women.
To the best of our knowledge, this was the first time that a Brazilian cohort of healthy nulliparous pregnant 
women received follow-up with data acquisition on the incidence of preeclampsia. The manner of calculating the 
rate of weight gain was a limitation of our analysis. Patients were recruited from 19 to 21 weeks of gestation to the 
Characteristics Preeclampsia Controls RR (95% CI)
Maternal age (years) n (%) n (%)
<20 20 (23) 271 (25.1) 0.91 [0.48–1.74]
20–34 60 (69) 736 (68.2) Ref.
>34 7 (8) 71 (6.7) 1.19 [0.50–2.85]
Ethnicity
White 27 (31) 435 (40.3) Ref.
Others 60 (69) 643 (59.7) 1.46 [0.84–2.55]
Marital statusa
With partner 63 (72.4) 777 (72.0) Ref.
Without partner 24 (27.6) 296 (27.4) 1.00 [0.47–2.12]
Schooling (years)
<12 58 (66.6) 733 (68.0) Ref.
≥12 29 (33.4) 345 (32.0) 1.06 [0.45–2.51]
Annual Family Income (US$)
Up to 3000 24 (27.6) 280 (25.9) 1.18 [0.63–2.23]
3000 to 6000 31 (35.6) 350 (32.4) 1.22 [0.64–2.34]
Above 6000 32 (36.8) 448 (41.7) Ref.
Source of prenatal care
Entirely public 81 (93.1) 927 (85.9) 2.10 [0.50–8.93]
Private/insurance/mixed 6 (6.9) 151 (14.1) Ref.
Family history of hypertensive disease
Any hypertensive disorderb 16 (18.4) 141 (13.0) 1.47 [0.83–2.60]
Pregnancy of participant’s mother 4 (4.6) 43 (3.9) 1.15 [0.12–10.62]
Smoking
No smoking 81 (93.1) 997 (92.4) Ref.
Stopped during pregnancy/current smoker 6 (6.9) 81 (7.5) 0.92 [0.18–4.58]
Use of illicit drugsc
Non-user 68 (78.2) 873 (80.9) Ref.
Ceased during pregnancy/current user 2 (2.3) 52 (4.8) 0.51 [0.22–1.22]
Weight gain rate per week (kg)d
<0.25 14 (16.1) 127 (11.7) 1.67 [0.42–6.59]
0.25–0.49 23 (26.4) 364 (33.7) Ref.
0.50–0.74 26 (29.9) 367 (34.0) 1.11 [0.70–1.77]
≥0.75 15 (17.2) 109 (10.1) 2.04 [1.12–3.69]
Body Mass Index at enrolmente,&
Underweight (<21.5 kg/m2) 9 (10.3) 190 (17.6) 0.74 [0.38–1.45]
Normal weight (21.5–26.2) 28 (32.2) 433 (40.1) Ref.
Overweight (26.3–30.9) 22 (25.3) 280 (25.9) 1.20 [0.75–1.92]
Obesity (>30.9) 28 (32.2) 174 (16.1) 2.28 [1.39–3.74]
Any previous maternal conditions (anaemia, thyroid, asthma, previous hypertensive disorder*, 
depression, POS)
No 53 (60.9) 730 (67.7) Ref.
Yes 34 (39.1) 348 (32.3) 1.31 [0.66–2.60]
Diastolic pressure at 20 weeks’ gestatione
<75 mmHg 64 (73.6) 937 (86.9) Ref.
≥75 mmHg 23 (26.4) 140 (12.9) 2.21 [1.30–3.74]
Total 87 1078
Table 1. Estimated risk of selected socio-demographic and some medical history and personal characteristics 
in preeclampsia. Missing information for a5; b100; c170; d120; e1case; #RR and 95% CI not presented due to small 
numbers; values in bold mean they are significant. *Without using medication. & ref.41.
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last measurement at the end of prenatal care. Owing that the last time measure was done between 37 and 39 weeks 
of gestation, a quarter of preeclampsia cases (22.9%) were not included. Potential bias – reverse causality – may 
occur, since after preeclampsia is diagnosed, weight is influenced by oedema, a potential feature of this disease. 
Another limiting characteristic is that the database does not have information on the precise time when antihy-
pertensive drugs (if used) were initiated.
In our cohort, data on the actual incidence of preeclampsia was totally distinct from findings of a systematic 
review published in 2008 showing a prevalence of 1.5% for preeclampsia and 0.6% for eclampsia. According to 
those authors, their numbers were underestimated in some regions due to lack of information8. Almost 10 years 
later, a study implemented in Brazil showed that the prevalence of preeclampsia was 8.1% in specific regions21. 
Our study currently revealed that the incidence of preeclampsia is 7.5% in a nulliparous group of healthy pregnant 
women, which is higher than values obtained from other cohorts16–18. The high prevalence of obesity in our popu-
lation may explain the incidence of preeclampsia. Despite the lack of data available on this topic in our country, a 
Characteristics Preeclampsia n (%) Controls n (%) RR (95% CI)
Mode of delivery
Vaginal 21 (24.1) 599 (55.5) Ref.
C-section 66 (75.9) 479 (44.5) 3.58 [1.57–8.12]
Onset of labour
Spontaneous 18 (20.7) 664 (61.5) Ref.
Induced 36 (41.4) 211 (19.5) 5.52 [2.21–13.83]
Elective C-section 33 (37.9) 203 (19.0) 5.30 [1.25–22.38]
Gestational age at birth (weeks)
<34 11 (12.6) 32 (3.0) 3.97 [1.55–10.20]
34–36 9 (10.3) 73 (6.7) 1.70 [0.57–5.06]
≥37 67 (77.1) 973 (90.3) Ref.
Length of postpartum hospitalization
1–4 days 67 (77.0) 1041 (96.5) Ref.
≥5 days 20 (23.0) 37 (3.5) 5.80 [2.12–15.91]
Thromboembolic event before or after delivery
No 87 (100.0) 1072 (99.4) Ref.
Yes 0 4 (0.4) #
Mean (SD) birthweight (g) 2779.4 (±843.1) 3158.8 (±558.9) *WMD = −379.4 (−644.5 to −114.4)
Adequacy of birthweight to GAa
SGA (p < 10) 22 (25.3) 124 (11.5) 2.45 [1.52–3.95]
AGA (10 < p < 90) 54 (62.0) 824 (76.4) Ref.
LGA (p > 90) 10 (11.5) 118 (10.9) 1.27 [0.76–2.13]
Fetal death 1 (1.1) 6 (0.5) 1.92 [0.09–39.42]
Apgar score – at 5 minutes <7b 3 (3.4) 16 (1.5) 2.11 [1.03–4.29]
Intubation required after birth 7 (8.0) 19 (1.7) 3.89 [0.41–36.95]
NICU admission 32 (36.7) 141 (13.1) 3.34 [1.61–6.90]
Neonatal Near Miss (Apgar 5 < 7 
OR Birthweight <1750 g OR GA 
<33)c
13 (14.9) 39 (3.6) 3.65 [1.78–7.49]
Total 87 1078
Table 2. Maternal and neonatal outcomes associated with preeclampsia. Missing information for a13 cases; b65 
cases; c62 cases. Values in bold mean they are significant. #RR and 95% CI not presented due to small numbers. 
*WMD: weighted mean difference.
Characteristics RRadj (95% CI)
Diastolic blood pressure at 20 weeks’ gestation 
(mmHg) 1.04 [<1.01–1.06]
Body Mass Index at enrolment (kg/m2) 1.04 [1.01–1.09]
Table 3. Factors independently associated with preeclampsia on multivariate analysis [n = 1164]. Variables included 
in the model (14): Maternal age (years); Ethnicity (White: 0/other: 1); Marital status (with partner: 0/without  
partner: 1); Schooling (<12 years: 0/≥12 years: 1); Annual Family Income (Up to US$6000: 1/>US$6000: 0); Source 
of prenatal care (entirely public: 1/other: 0); Family history of hypertensive disease: Any hypertensive disorder (yes: 
1/no: 0); Pregnancy of participant´s mother (yes: 1/no: 0); Smoking (yes: 1/no smoking: 0); Use of illicit drugs (yes: 
1/non-user:0); Weight gain rate per week (kg); Body Mass Index at enrolment (kg/m2); Any previous maternal 
conditions (yes: 1/no: 0); Diastolic blood pressure at 20 weeks’ gestation (mmHg).
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recent cross-sectional study involving 1,279 pregnant women showed that the prevalence of overweight or obesity 
during the first prenatal visit was almost 40%22.
Owing to the high incidence and the potential impact of preeclampsia2,23,24, it is essential to find an effective 
tool that provides early identification of pregnant women at high risk for this disease, in order to implement 
prophylactic measures and avoid harmful consequences. A search for a predictive model with widespread global 
applicability has begun, encouraged by the results achieved by studies using low-dose aspirin as a prophylactic 
measure25,26. However, the prediction of preeclampsia is challenging, in view of the complexity of its aetiology27. It 
is unlikely that a single risk factor will be able to predict the occurrence of this condition. In addition, our results 
come from women that were initially screened at around 20 weeks, after the period when some known prophy-
lactic measures are recommended to be started.
Maternal clinical factors have emerged as an interesting screening alternative. In 2010, a guideline of the 
National Collaborating Centre for Women’s and Children’s Health recommended the use of maternal clinical 
factors as screening tests. According to the guideline, a previous history of gestational hypertensive disorder, 
autoimmune disease (systemic erythematous lupus or antiphospholipid syndrome), chronic renal disease, dia-
betes and chronic hypertension are considered high-risk factors. Once any of these factors are present, prophy-
lactic measures must be initiated28. The NICE screening proposal was assessed in a prospective study involving 
a heterogeneous population composed of nulliparous and multiparous pregnant women. Detection rates of 37% 
and 28.9% were obtained for early-onset (before 34 weeks of gestation) and late-onset (at or after 34 weeks of 
gestation) preeclampsia cases, respectively29. These numbers were confirmed in another study applying the NICE 
criteria with a third of preeclampsia cases identified30.
Our cohort identified only three factors related to increased risk of preeclampsia: weight gain rate per week, 
obesity and value of diastolic blood pressure measured at 20 weeks of gestation equal to or higher than 75 mmHg. 
A cohort of more than 62,000 nulliparous pregnant women generated the same finding concerning the influence 
of weight gain per week on preeclampsia risk18. We also reinforced previous evidence that obesity predisposes to 
the occurrence of preeclampsia, especially in late-onset cases. This is probably associated with the inflammatory 
property of adipose tissue and its effects on endothelial function31. Considering that both BMI and weight gain 
rate are modifiable risk factors, consolidated knowledge of their predictive function emphasises the importance 
of antenatal counselling and prenatal care follow-up32,33.
Our cohort of nulliparous healthy pregnant women also indicated that a diastolic blood pressure higher than 
75 mmHg was correlated with the occurrence of preeclampsia. This finding conflicts with another study34, which 
showed that mean arterial blood pressure was a better predictor of preeclampsia in a healthy group of pregnant 
women.
The modest predictive power achieved through models with only maternal clinical factors have prompted pro-
spective studies among heterogeneous populations. These studies used multivariate analysis combining maternal 
clinical factors to other elements such as uterine artery Doppler and biomarkers, in order to develop algorithms 
of preeclampsia prediction. Although the detection rates of the resulting algorithms were high, these studies were 
implemented among a heterogeneous population of pregnant women at high risk of developing preeclampsia29,30. 
Furthermore, these studies did not segregate nulliparous women, which is a limitation. It is well-known that the 
most consistent predictive clinical factor for preeclampsia, which is a previous history of preeclampsia, cannot be 
applied to first-time mothers3.
Biochemical factors have been studied, with modest results in terms of prediction potential35,36. Furthermore, 
the potential costs incurred and technologies available for biomarker processing represent a limiting factor for 
use on a large scale, especially in low and middle-income countries. Thus, clinical risk factors continue to play a 
crucial role as a cheap and tangible screening instrument for preeclampsia.
To date, no single screening test has shown sufficiently accurate specificity and sensitivity to predict preec-
lampsia cases37. The value of clinical risk factors, biochemical markers, uterine Doppler as predictive markers 
addressed separately remains modest at best for all women destined to develop preeclampsia38. This is probably 
due to the multifactorial aetiology of the condition. Genetic, immunological, environmental and maternal factors 
have all made their contributions and remain to be fully elucidated. Therefore, preeclampsia is a heterogene-
ous disease concerning clinical presentation, pathology and outcomes. Notwithstanding decades of research, 
an enigma still persists surrounding a useful and accurate screening test model to identify early on pregnant 
women, primarily in the nulliparous group, at high risk for preeclampsia. Research into this field is of consider-
able importance.
Methods
This is a nested case-control study derived from a secondary analysis of the Preterm-SAMBA study (Preterm 
Screening and Metabolomics in Brazil and Auckland), a prospective multicentre cohort study conducted in five 
Brazilian centres between July 2015 and March 2018. The research protocol was previously published elsewhere39. 
Briefly, the original study design was based on the primary goal of developing a predictive model for preterm 
birth. The study was developed in two phases: a discovery phase and a validation phase. The first phase was a 
case-control study, involving participants from the previously described SCOPE study3. In the validation phase, a 
prediction model was validated in the Preterm SAMBA Brazilian cohort. Other maternal and perinatal outcomes 
of interest were considered as secondary objectives included preeclampsia (currently addressed), gestational dia-
betes mellitus and fetal growth restriction. For this nested case-control approach, cases were women who devel-
oped preeclampsia and controls were all the remaining women free from the disorder. Preterm-SAMBA study 
was conducted according to Declaration of Helsinki guidelines. Appropriate approval was obtained from the five 
centres involved in the study. All recruited participants gave their written informed consent.
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participants. The study enrolled healthy nulliparous pregnant women between 19 and 20 + 6 weeks of gesta-
tion, with a singleton pregnancy, from five different centres in Brazil (from Campinas, Botucatu, Recife, Fortaleza 
and Porto Alegre). Exclusion criteria were: 3 or more previous abortions; cervical suture; fetal malformation; 
chronic hypertension requiring antihypertensive drugs and/or diabetes and/or renal disease; arterial blood pres-
sure higher than 160 × 100 mmHg at the time of enrolment; Systemic Lupus Erythematosus and/or antiphos-
pholipid syndrome; sickle cell disease; HIV infection; congenital uterine anomalies (bicornuate uterus, septate 
uterus); previous cervical knife cone biopsy; chronic exposure to corticosteroids or calcium at a dosage above 1 g 
or fish oil at a dosage above 2.7 g per day or vitamin C above 1000 mg per day or vitamin E above 400 UI per day; 
heparin or aspirin use (any dosage or presentation form). Our inclusion and exclusion criteria were decided to 
be aligned with another study, previously published called SCOPE3 that used exactly the same criteria. This is the 
reason why obesity was not considered exclusion criteria, although for some authors it is considered a major risk 
factor for preeclampsia27.
sample size estimation. Sample size was calculated according to the primary outcome - preterm birth. 
Assuming a type I error of 5% and accuracy of the test of at least 0.68 according to the area under the ROC curve, 
and to test the hypotheses with adequate power (80% of power, β = 0.2), the sample size would need to approach 
80 cases of preterm delivery. The minimum expected prevalence of this outcome was presumed to be 7% in Brazil, 
therefore the sample size was calculated at 1150 women. In addition, considering that the mean prevalence of 
preeclampsia observed in larger studies of around 5–6%8,17 among nulliparous women, it was anticipate that this 
cohort would incorporate around 58 to 69 cases of preeclampsia.
procedures. All steps of the main study have been previously described39. Data were collected at three differ-
ent set points (visits) during follow-up. On the first visit, between 19 and 21 weeks of gestation, a full assessment 
was performed to gather information on sociodemographic characteristics, reproductive family history, cur-
rent or previous diseases, personal habits, with a complete follow-up until delivery and immediate postpartum 
period. During the interview, data were entered into a central database with internet access and complete audit 
trail (MedSciNet). Anthropometric measurements plus nutritional assessment were also performed. The same 
evaluation was conducted on both subsequent visits, at 27–29 weeks of gestation and at 37–39 weeks of gestation.
outcome. The outcome of interest for the current analyses is preeclampsia. In this study, preeclampsia was 
defined as the occurrence of hypertension (SBP ≥ 140 and/or DBP > 90 mmHg) in at least two different time peri-
ods, combined with proteinuria (300 mg/24 hour or at least 1 g/L [2+] on dipstick testing or spot urine protein/
creatinine >30 mg/mmol [0.3 mg/mg]). Preeclampsia was also classified as early-onset when diagnosed before 34 
weeks of gestation and as late-onset otherwise. In the absence of proteinuria, the disorder was also defined as the 
occurrence of any systemic complications/organ dysfunction40 including:
•	 Haematological complications (thrombocytopenia - platelet count below 100,000/dL, DIC, haemolysis);
•	 Hepatic dysfunction (elevated liver enzymes – at least twice the upper limit of normal + right upper quadrant 
or epigastric abdominal pain);
•	 Neurological dysfunction (eclampsia, altered mental status, blindness, stroke, hyperreflexia with clonus, 
severe headaches, visual scotomata when persistent);
•	 Renal dysfunction (creatinine ≥1.2 mg/dL).
statistical analysis. We determined the general incidence of preeclampsia and early-onset and late-onset 
preeclampsia. Several socio-demographic, clinical factors and lifestyle habits were regarded as potential risk 
factors. Furthermore, maternal and neonatal outcomes associated with preeclampsia were addressed. Bivariate 
analysis was performed, estimating the Risk Ratios (RR) and their respective 95% Confidence Intervals, using 
Student’s t, chi-square or Fisher’s exact tests accordingly. Finally, a multivariate analysis with a Poisson regression 
model was performed to identify which factors were independently associated with preeclampsia in this sample, 
estimating the adjusted RR for those identified. Each centre/hospital was considered as a Primary Sampling Unit 
(PSU) in every analysis. SPSS software version 20.0 and Stata software version 7.0 were used for analysis.
ethical considerations. The current study is an ancillary analysis (preeclampsia) of the outcome from a 
Brazilian cohort of low-risk nulliparous women entitled “Preterm SAMBA” which was financially supported by 
the Bill and Melinda Gates Foundation and the Brazilian CNPq. The Preterm SAMBA study has been reviewed 
and approved by the Brazilian National Committee for Ethics in Research (CONEP) and by the Institutional 
Review Board (IRB) of the coordinating centre (Letter of approval 1.048.565 issued on 28th April 2015) and of 
all other Brazilian participating centres. Before enrolment, each woman was full explained about the study and 
signed an informed consent form.
Data Availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request. The participating women did not give their consent to make their own data publicly available.
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